Projects

Norrsken Mind advances psychedelic science in Europe. We fund research, education and implementation projects projects related to psychedelic therapies.

Grants awarded

Policy

Setting New Standards for Psychedelic Evidence Assessment

Norrsken Mind is funding the Independent Psychedelic Evidence Assessment Working Group (IPEA-WG) to develop new, rigorous and multidisciplinary standards for evaluating evidence related to psychedelic therapies. The project is led by Eduardo Schenberg, MSc, PhD (Faculty of Medicine, University of Lisbon), with co-chairs Franklin King, MD (Massachusetts General Hospital) and Marion Haberkamp, MD (German Federal Institute for Drugs and Medical Devices, BfArM).

Policy

Paving the Way for Implementing Psychedelic Therapies in Europe

Norrsken Mind is a founding member and supporter of the Psychedelic Access and Research European Alliance (PAREA), a non-profit, multidisciplinary partnership advancing the safe, ethical, and equitable integration of psychedelic-assisted care into European healthcare.

Education

Comparative Assessment of Treatments for Treatment-Resistant Depression

Drug Science will convene a panel of clinical experts, alongside patient representatives, to evaluate treatments for treatment-resistant depression (TRD). Using a multi-criteria decision analysis (MCDA) framework, the project will assess both therapeutic benefits and safety across a wide range of interventions, including psychedelic treatments. The findings are intended to inform clinical practice, regulatory decision-making, and policy development.

Study

The Open Psilocybin Study

Norrsken Mind is supporting the Open Psilocybin Study (OPS), an innovative multi-session experimental study at Leiden University and the Centre for Human Drug Research (CHDR), designed to investigate how low-to-medium doses of psilocybin affect the brain, body, and self-perception compared to placebo. The study will recruit 40 healthy participants and is led by Associate Professor Michiel van Elk, in collaboration with researchers at the CHDR.

Study

Psilocybin-assisted therapy for Anorexia Nervosa

A randomized controlled trial to evaluate the effectiveness, safety and tolerability of psilocybin, in comparison to standard treatment, for young adults with severe anorexia nervosa. The study will involve 40 participants and is led by Pouya Movahed Rad, Senior researcher, at Lund University.

Study

The Psychotherapeutic Component of Psilocybin Treatments for Depression

A project at Karolinska Institutet to analyze data from two clinical trials, featuring more than 120 patients, to better understand the therapeutic framework needed for safe and effective administration of psilocybin for depression.

Study

The Psychotherapeutic Framing and Setting in Psilocybin Therapy

Norrsken Mind is co-funding a planned RCT at the University of Copenhagen to evaluate the short- and long-term effects of psilocybin for depression when administered within a psychotherapeutic framework versus a medical support model.

Education

Borealis Psychedelic Science Summit 2025

Norrsken Mind was a main partner of the Borealis Psychedelic Science Summit 2025, together with Nostromo Foundation. The summit was held in Stockholm on September 26–27. The event brought together over 300 participants from 21 countries for Sweden’s second national psychedelic science conference. Organized by the Swedish Network for Psychedelic Science (NPV), the summit explored the latest advances in psychedelic research and their translation into clinical and policy contexts.

Study

The Neurobiological and Cognitive Mechanisms Behind Psilocybin-assisted Therapy

Researchers at Karolinska Institutet investigates the cognitive and neurobiological changes associated with psilocybin-assisted therapy, which may offer insights into the neurobiology of major depressive disorder and the therapeutic mechanisms of psilocybin.

Education

Group Ketamine-Assisted Psychotherapy for Ukrainian Veterans

Norrsken Mind is supporting Heal Ukraine Trauma (HUT) in expanding a training program that prepares psychotherapists, psychologists, and psychiatrists in Ukraine to provide group Ketamine-Assisted Psychotherapy (KAP) for military veterans. HUT is an initiative of Heal Traumas International, Inc., a U.S. non-profit organization founded in 2022 to build sustainable, evidence-based mental health solutions in conflict-affected settings.

Study

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

Norrsken Mind funded the first Swedish clinical trial using a psilocybin-assisted therapy protocol. At Karolinska Institutet, the study investigates the effects of psilocybin on symptoms of depression and synaptic density.

Education

Reimbursement Pathways for Psychedelic Therapies in Europe

Norrsken Mind is funding a research project to produce a comprehensive report on reimbursement pathways for psychedelic treatments in Europe. The project is led by Floris Wolswijk, founder of Blossom (a psychedelic science and insight platform), and Martin Gisby, independent healthcare consultant with over 15 years of experience.

Study

MDMA-Assisted Psychotherapy for Young Adults with Major Depressive Disorder

Norrsken Mind has granted partial funding to a study under planning at Umeå University to investigate MDMA-assisted psychotherapy as a treatment for depression in young adults (aged 18-25).

Study

Genetic & Environmental Contributions to Psychiatric Risks & Benefits of Psychedelic Use in Vulnerable Populations

Norrsken Mind is funding a project at Karolinska Institutet to investigate the genetic and environmental contributions to psychiatric risks and benefits of psychedelic use in vulnerable populations.

Study

Psychedelic Use and Markers of Physical Health

An epidemiological research program at Karolinska Institutet by Otto Simonsson, PhD, and Walter Osika, MD PhD, focused on investigating the link between the use of classic psychedelics and different somatic disorders

Study

The Adolescent and Young Adult Use and Experience of Psychedelics

A project investigating the adolescent and young adult use and experience of psychedelics in two different and natural settings through survey, longitudinal observation, and in-depth interviews.

Education

Nordic Psychedelic Science Conference 2022

The Nordic Psychedelic Science Conference (NPSC) in Oslo, Norway, on the May 19-20th, 2022.

Do you have a project in need of funding?

Norrsken Mind’s purpose is to advance the field of psychedelic science in Europe. We fund projects related to psychedelic science in the areas of research, education, and implementation.

Apply for funding